Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen.
about
A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatmentImpact of glutathione-S-transferases (GST) polymorphisms and hypermethylation of relevant genes on risk of prostate cancer biochemical recurrence: a meta-analysisHypermethylation of genes for diagnosis and risk stratification of prostate cancerThe effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databasesAssociation of cigarette smoking with interval to biochemical recurrence after radical prostatectomy: results from the SEARCH database.Polycyclic aromatic hydrocarbon--DNA adducts in prostate and biochemical recurrence after prostatectomySalvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges.Benchmarks for operative outcomes of robotic and open radical prostatectomy: results from the Health Professionals Follow-up StudyCigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database.Selenium supplementation and prostate cancer mortalityGenetic interaction analysis of TCF7L2 for biochemical recurrence after radical prostatectomy in localized prostate cancer.Genetic variants in the Hippo pathway predict biochemical recurrence after radical prostatectomy for localized prostate cancer.Diagnosis of local recurrence after radical prostatectomy.Milk and dairy consumption among men with prostate cancer and risk of metastases and prostate cancer death.Recent changes in the clinicopathologic features of Korean men with prostate cancer: a comparison with Western populations.PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer.Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database.Genetic variants of the autophagy pathway as prognostic indicators for prostate cancer.Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer.Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies.The incremental value of contrast-enhanced MRI in the detection of biopsy-proven local recurrence of prostate cancer after radical prostatectomy: effect of reader experience.Circulating fibroblast-like cells in men with metastatic prostate cancer.Rising prostate-specific antigen after primary prostate cancer therapy.Predictive factors for biochemical recurrence in radical prostatectomy patientsSmoking and prostate cancer survival and recurrence.Genetic variants in ultraconserved regions associate with prostate cancer recurrence and survivalDefinition and management of prostate-specific antigen recurrence after local therapy.Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.Prognostic Value of Prostaglandin-endoperoxide Synthase 2 Polymorphisms in Prostate Cancer Recurrence after Radical ProstatectomyPrognostic significance of fibroblast growth factor receptor 4 polymorphisms on biochemical recurrence after radical prostatectomy in a Chinese population.Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy.Ultrasensitive Luminescent In Vitro Detection for Tumor Markers Based on Inorganic Lanthanide Nano-Bioprobes.Prognostic Relevance of Methylenetetrahydrofolate Reductase Polymorphisms for Prostate Cancer.Treatment of men with rising prostate-specific antigen levels following radical prostatectomy.Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis.Prognostic factors for the development of biochemical recurrence after radical prostatectomy.Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival.Effects of definitive and salvage radiotherapy on the distribution of lymphocyte subpopulations in prostate cancer patients.Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.
P2860
Q26862558-0FC60D8D-F274-4DA7-80C3-DADDF818888AQ28533760-DA94AA9D-F834-4D01-A036-DF87600C0430Q33410858-1325EF70-9330-4BA6-921F-770FC7A4CADAQ33516060-37F1FD73-5A6F-4D15-975A-BEE53C1ED30FQ33551851-47246FF2-F047-4AFA-8544-FEDC6D3BE443Q33641222-978F458A-0A9F-47F2-95DA-A844693B3B5EQ33766462-50BA5B54-5F79-466B-B6CD-5EF2D8FA03B7Q34028700-E925185B-2A7C-42E6-BFC6-4275D3F442A9Q34108249-3E9C5B31-5528-4CEE-BE2E-BB7B5D5B83D2Q34974869-9FF96002-F69A-4E3C-B78B-466DE3F34CCFQ35069181-FD77746C-E463-4D3A-A940-272F68B7E821Q35113863-3A813F46-E47C-4C57-A3A0-88122EB3CD3CQ35685876-61D78614-3040-4070-875D-986184DCCFABQ35815607-0B45D88E-6A5F-464A-8494-62C1E21ACAD5Q35932204-9695B135-7C5B-4A8D-BD55-0CF07BB30BE3Q36023904-BBF30CC3-83E4-43DA-982E-14A2B4A3D6F1Q36044706-20B3B52E-ACE1-47FB-8816-F2B6778C31B0Q36056250-3B52BAA7-29D1-40B5-94B0-C4D018F784F4Q36173646-85B13E68-F365-491F-8731-EEFFADE96FA5Q36272854-4FD874CC-BC54-44AC-A8AA-02FA9C573869Q36290824-A4E7E935-C4B6-40A7-AAF0-80E6C67B094FQ36351155-EAEA664A-BD3A-434D-AB4D-C749E1ED08F3Q36395149-B3893750-58D3-4152-BA39-F6A444A3BFBCQ36547490-7FA4F8BF-04D6-418E-8B94-FB14B8D535CDQ36581779-D0C3C9B3-5D94-4E36-9967-6711D8547203Q36606039-FCC6C310-8FF3-4BAF-BAE8-26A18E672ED5Q36861760-E1C16DEF-7BE8-4338-88F3-1871D76482B8Q37209816-DB8B6FF8-DADE-4F43-86A6-607CFF318C9DQ37263499-E0EF3BA2-A062-4233-A4EA-CE3FBEA64F27Q37264491-A582F389-EF81-46C2-B456-0F5750088BC7Q37280719-8157F0A3-9939-455B-9CF4-16DD4EF22955Q37399907-A09B49F1-02B2-46D4-B3AA-F891FF9A4328Q37404644-9BE7382F-4063-46FC-B05B-52EDA345F3F2Q37534571-81C8AB19-147A-4C3A-B1E7-C94DE3AEF11CQ37821906-24D8624E-8720-4D7B-A2C5-F7586DAEB1EFQ37957382-8350F2CB-2E3F-470F-BF2D-CB9FB015C48BQ37960019-8B394EBA-12B3-43C9-8094-6726BB8AD6D9Q38620741-51E93390-8B74-4A99-B021-7395E0212BECQ38788456-B32259EF-04B3-4139-AF85-090EE4531898Q38833159-2157C170-CDF4-4DFE-82A6-2443101EEE80
P2860
Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Defining the ideal cutpoint fo ...... my. Prostate-specific antigen.
@ast
Defining the ideal cutpoint fo ...... my. Prostate-specific antigen.
@en
Defining the ideal cutpoint fo ...... my. Prostate-specific antigen.
@nl
type
label
Defining the ideal cutpoint fo ...... my. Prostate-specific antigen.
@ast
Defining the ideal cutpoint fo ...... my. Prostate-specific antigen.
@en
Defining the ideal cutpoint fo ...... my. Prostate-specific antigen.
@nl
prefLabel
Defining the ideal cutpoint fo ...... my. Prostate-specific antigen.
@ast
Defining the ideal cutpoint fo ...... my. Prostate-specific antigen.
@en
Defining the ideal cutpoint fo ...... my. Prostate-specific antigen.
@nl
P2093
P1433
P1476
Defining the ideal cutpoint fo ...... my. Prostate-specific antigen.
@en
P2093
Frederick Dorey
Mark E Sutter
Stephen J Freedland
William J Aronson
P304
P356
10.1016/S0090-4295(02)02268-9
P407
P577
2003-02-01T00:00:00Z